Enable Injections Secures $30M Sanofi Investment for On-Body Delivery System Expansion
January 11, 2026, 3:45 am
Location: United States
Employees: 51-200
Founded date: 2010
Total raised: $275M
Location: United States, Massachusetts, Cambridge
Employees: 10001+
Founded date: 1981
Total raised: $1.1B
Enable Injections receives a $30 million investment from Sanofi. This capital targets a major manufacturing expansion for its enFuse On-Body Delivery System. The wearable technology delivers large-volume subcutaneous medicines. Funds also bolster supply chain capabilities. They accelerate commercial growth globally. This move reinforces a multi-year partnership. Enable Injections plans a new manufacturing center in Ohio. The investment addresses escalating demand from pharmaceutical partners. It ensures patients gain access to convenient, advanced drug delivery solutions. The enFuse system boasts U.S. FDA approval and international marketing authorizations. This financial commitment marks a significant step for innovative healthcare technology. It aims to transform patient treatment experiences worldwide.
Enable Injections strengthens its position. The Cincinnati-based healthcare innovator secured a $30 million investment. Pharmaceutical giant Sanofi provided the capital. This funding targets critical growth. It will expand manufacturing for the enFuse On-Body Delivery System. This system represents a significant advance in drug administration.
The enFuse system is a wearable injector. It delivers large volumes of medicines subcutaneously. Patients benefit from its design. It features a push-button start. A hidden, retractable needle enhances safety. The system allows for hands-free administration. This promotes patient independence. It improves convenience for those managing chronic conditions.
Sanofi's investment accelerates manufacturing build-out. It bolsters supply chain capabilities. It directly supports commercial growth. The demand for enFuse technology is rising. Pharmaceutical partners require increased production. Programs progress towards commercialization. This capital ensures Enable Injections meets those needs.
This investment underscores a deep partnership. Enable Injections and Sanofi share a multi-year relationship. Sanofi utilized the enFuse injector in key clinical studies. These included Sarclisa trials. The IRAKLIA phase 3 study focused on newly diagnosed multiple myeloma. The IZALCO phase 2 study involved relapsed or refractory multiple myeloma. These trials showcased enFuse capabilities. Regulatory review for Sarclisa use with enFuse is currently underway.
Enable Injections has a strong financial history. Sanofi led a $50 million Series B round in 2018. A formal partnership announcement followed in 2019. The company later closed a $215 million Series C financing. This occurred in January 2022. Magnetar Capital led that round. Sanofi also participated. Other institutional investors joined. Existing regional and strategic investors maintained support. This consistent backing highlights confidence. Investors believe in the enFuse platform's potential.
Manufacturing expansion remains a top priority. Enable Injections announced ambitious plans in 2024. A 90,000-square-foot Manufacturing Center of Excellence is underway. This facility is located in Springdale, Ohio. Enhancements to its corporate headquarters also proceed. The Evendale, Ohio, site sees improvements. This strategic move aims for in-house, large-scale production. It supports global commercialization efforts. The company seeks to control its supply chain. It prioritizes efficient, high-volume manufacturing.
Regulatory milestones validate the technology. The enFuse system received its first U.S. FDA approval in 2023. This approval was part of a combination product. This marked a crucial step. It opened doors to the U.S. market. Since then, the technology secured device marketing authorizations. Multiple markets outside the U.S. have approved it. This global reach ensures wider patient access.
The enFuse system addresses a critical need. Many modern biologic therapies require large-volume injections. Traditional methods often involve clinic visits. Intravenous infusions are common. The enFuse system offers an alternative. It allows patients to self-administer at home. This reduces healthcare burdens. It enhances patient comfort and convenience. Oncology patients particularly benefit. Complex treatment regimens become more manageable.
Michael D. Hooven leads Enable Injections. As CEO, he champions the enFuse platform. The company's vision centers on patient experience. The goal is to simplify complex treatments. Large-volume subcutaneous injectables become more accessible. This investment helps fulfill that mission.
The future of drug delivery is evolving. Wearable technology plays a key role. Enable Injections stands at the forefront. Their enFuse system represents innovation. It promises a better quality of life for patients. The Sanofi investment fuels this progress. It secures critical manufacturing capabilities. It strengthens a vital partnership. This ensures the delivery of groundbreaking therapies. Enable Injections continues its path toward transforming patient care. Its impact will extend worldwide.
Enable Injections strengthens its position. The Cincinnati-based healthcare innovator secured a $30 million investment. Pharmaceutical giant Sanofi provided the capital. This funding targets critical growth. It will expand manufacturing for the enFuse On-Body Delivery System. This system represents a significant advance in drug administration.
The enFuse system is a wearable injector. It delivers large volumes of medicines subcutaneously. Patients benefit from its design. It features a push-button start. A hidden, retractable needle enhances safety. The system allows for hands-free administration. This promotes patient independence. It improves convenience for those managing chronic conditions.
Sanofi's investment accelerates manufacturing build-out. It bolsters supply chain capabilities. It directly supports commercial growth. The demand for enFuse technology is rising. Pharmaceutical partners require increased production. Programs progress towards commercialization. This capital ensures Enable Injections meets those needs.
This investment underscores a deep partnership. Enable Injections and Sanofi share a multi-year relationship. Sanofi utilized the enFuse injector in key clinical studies. These included Sarclisa trials. The IRAKLIA phase 3 study focused on newly diagnosed multiple myeloma. The IZALCO phase 2 study involved relapsed or refractory multiple myeloma. These trials showcased enFuse capabilities. Regulatory review for Sarclisa use with enFuse is currently underway.
Enable Injections has a strong financial history. Sanofi led a $50 million Series B round in 2018. A formal partnership announcement followed in 2019. The company later closed a $215 million Series C financing. This occurred in January 2022. Magnetar Capital led that round. Sanofi also participated. Other institutional investors joined. Existing regional and strategic investors maintained support. This consistent backing highlights confidence. Investors believe in the enFuse platform's potential.
Manufacturing expansion remains a top priority. Enable Injections announced ambitious plans in 2024. A 90,000-square-foot Manufacturing Center of Excellence is underway. This facility is located in Springdale, Ohio. Enhancements to its corporate headquarters also proceed. The Evendale, Ohio, site sees improvements. This strategic move aims for in-house, large-scale production. It supports global commercialization efforts. The company seeks to control its supply chain. It prioritizes efficient, high-volume manufacturing.
Regulatory milestones validate the technology. The enFuse system received its first U.S. FDA approval in 2023. This approval was part of a combination product. This marked a crucial step. It opened doors to the U.S. market. Since then, the technology secured device marketing authorizations. Multiple markets outside the U.S. have approved it. This global reach ensures wider patient access.
The enFuse system addresses a critical need. Many modern biologic therapies require large-volume injections. Traditional methods often involve clinic visits. Intravenous infusions are common. The enFuse system offers an alternative. It allows patients to self-administer at home. This reduces healthcare burdens. It enhances patient comfort and convenience. Oncology patients particularly benefit. Complex treatment regimens become more manageable.
Michael D. Hooven leads Enable Injections. As CEO, he champions the enFuse platform. The company's vision centers on patient experience. The goal is to simplify complex treatments. Large-volume subcutaneous injectables become more accessible. This investment helps fulfill that mission.
The future of drug delivery is evolving. Wearable technology plays a key role. Enable Injections stands at the forefront. Their enFuse system represents innovation. It promises a better quality of life for patients. The Sanofi investment fuels this progress. It secures critical manufacturing capabilities. It strengthens a vital partnership. This ensures the delivery of groundbreaking therapies. Enable Injections continues its path toward transforming patient care. Its impact will extend worldwide.